Document is current

Article History

Received: 10 September 2020

Accepted: 10 November 2020

First Online: 25 November 2020

Compliance with ethical standards

:

: This study is not industry-sponsored.Francisco Pérez-Miralles has received compensation for serving on scientific advisory boards or for speaking honoraria from Almirall, Biogen Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi Aventis, and Teva.Jordi Río has received compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen Idec, and Novartis.Deborah Pareto has received honoraria as speaker from Novartis, and Genzyme.Àngela Vidal-Jordana receives support for contracts Juan Rodes (JR16/00024) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, and has engaged in consulting and/or participated as speaker in events organized by Novartis, Roche, Teva, Mylan, Biogen, Merck, and Sanofi.Cristina Auger has received speaking honoraria from Novartis, Biogen, and Stendhal.Georgina Arrambide has received compensation for consulting services or participation in advisory boards from Biogen-Idec, Sanofi, and Merck; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, and Stendhal; and speaking honoraria from Sanofi and Merck.Joaquín Castilló has nothing to disclose.Mar Tintoré is co-editor of Multiple Sclerosis Journal - Experimental, Translational and Clinical. She has received compensation for consulting services and speaking from Almirall, Bayer-Schering, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, and Teva.Àlex Rovira serves/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Biogen IDEC, OLEA Medical, Synthetic MR, Icometrix, and Bayer, has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, and Biogen Idec, and has research agreements with Siemens AG.Xavier Montalban has received speaking honoraria and travel expenses for participation in scientific meetings and, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Actelion, Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon Genomics, Roche, Sanofi-Genzyme, and Teva Pharmaceutical.Jaume Sastre-Garriga has received compensation for serving on scientific advisory boards or in speaker’s bureaus from Biogen, Merck, Novartis, Almirall, Bial, Bayer, Teva, Roche, Celgene, and Sanofi-Genzyme. He serves in the editorial board of Multiple Sclerosis Journal and as Director of Revista de Neurología.

: Approval from the local ethics committee was received.

: Patients provided their written informed consent

: Not applicable.

: Not applicable.